From the Sector

The diabetic community has always been a priority for Hologenix, creators of CELLIANT® infrared technology, so the company embarked on an initial study to test the hypothesis that the technology can positively impact diabetic patients with vascular impairment, now published in Journal of Textile Science & Engineering. Another study is underway as well with more research on the horizon.

According to statistics cited in the International Diabetes Federation Diabetes Atlas, 9th edition, globally, close to a half billion people are living with diabetes and that number is expected to increase by more than 50 percent in the next 25 years.
 
The introduction of the study in the Journal of Textile Science & Engineering also reports that diabetic patients frequently suffer from a combination of peripheral neuropathy and peripheral artery disease, which particularly affects their feet. It further states that it has been estimated that the lifetime risk for the development of foot ulcers in diabetic patients can be as high as 25 percent and that the risk of amputation is 10 to 20 times higher than in non-diabetic subjects.
 
The study was performed by Lawrence A. Lavery, D.P.M., M.P.H., a Professor in the Department of Plastic Surgery at UT Southwestern Medical Center. His clinic and research interests involve diabetic foot complications, infections and wound healing, and he participated in the conception, design, implementation and authorship of the Journal of Textile Science & Engineering study.  

CELLIANT technology is a patented process for adding micron-sized thermo-responsive mineral particles to fibers, in this case polyethylene terephthalate (PET) fibers. The resulting CELLIANT yarns were woven into stockings and gloves containing either 82% CELLIANT polyester, 13% nylon and 5% spandex or for the placebo, 82% polyester with no CELLIANT, 13% nylon and 5% spandex. CELLIANT products absorb body heat and re-emit the energy back to the body as infrared energy, which is non-invasive and increases temporary blood flow and cell oxygenation levels in the body.

The objective of the study was to “evaluate changes in transcutaneous oxygen (TcPO2) and peripheral blood flow (laser Doppler, LD) in the hands and feet of diabetic patients with vascular impairment when CELLIANT gloves and stockings are worn.” While there was not a statistically significant result across all subjects, the study did show that some patients wearing CELLIANT stockings for 60 minutes had an increase of as much as 20% in tissue oxygenation and 30% in localized blood flow. According to the study’s conclusion, “the trends that were observed in favor of CELLIANT stockings suggest that a larger well-designed clinical trial should be undertaken and may provide evidence of clinical efficacy in treatment of the diabetic foot.”
 
The study also notes that “There have been no documented or observed side effects of wearing CELLIANT stockings, and they are relatively inexpensive compared to conventional pharmaceutical interventions.”

Hologenix has embarked on a more comprehensive trial, “Study to Evaluate CELLIANT Diabetic Medical Socks to Increase Tissue Oxygenation and Incidence of Complete Wound Closure in Diabetic Foot Wounds” – NCT04709419, which focuses on the impact of CELLIANT technology to potentially improve tissue oxygenation and wound healing outcomes.
 
“We are excited to explore whether future studies of infrared, with its most common biological effects of increased localized blood flow and cellular oxygenation, could result in a breakthrough in diabetic patients with vascular impairment,” said Seth Casden, Hologenix Co-founder and CEO. “We see a huge potential opportunity with this research for helping to fulfill our core mission of improving people’s health and well-being by potentially reducing the impact of diabetes, and we are actively seeking partners to expand our research efforts.”

• Harmful PFAS chemicals, used in thousands of consumer products, are shaping up to be the big environmental and health threat of our time. The EU is now the first in the world to propose a broad ban on these chemicals.
• Consumer brands worth more than €130 billion support the ban on PFAS.  
• Investors with assets in PFAS-producing companies are calling for an end to production.

Many companies are taking a stand against PFAS chemicals as the EU invites the public to give its opinions on the proposed ban on these harmful chemicals.

108 companies dedicated to phasing out PFAS chemicals from products and processes have joined the PFAS Movement, an advocacy campaign initiated by environmental NGO ChemSec that calls for comprehensive regulation of PFAS in the EU. The members comprise many well-known brands, such as Inditex, Urbanears and the Cookware Company, representing various industries— fashion, home goods, food, and personal care. The members are worth more than €130 billion in total revenue.

“A European ban on PFAS chemicals will have huge repercussions for all manufacturing industries and require much work for companies in the global supply chain. However, some parts of the industry oppose this ban, claiming that the change is too big to be justified. That’s why the support for a ban from such influential consumer brands as those in the PFAS Movement is so important. It’s a strong sign that businesses want to eliminate PFAS chemicals in products and processes”, says Anne-Sofie Bäckar, Executive Director at ChemSec.

A Hollywood Helping Hand
ChemSec’s PFAS Movement is not only supported by the brands but also by Hollywood actor Mark Ruffalo who became a PFAS activist after his involvement in the film Dark Waters. The film depicts the real-life events following the massive uncovering of PFAS contamination in the USA. As a result, several PFAS producers in the USA are now involved in multimillion-dollar lawsuits.

The health and environmental threats of PFAS, along with all the lawsuits, have also created attention among another influential group: institutional investors. Last year, 47 institutional investors with US$8 trillion in assets sent a letter to 54 chemical companies named by ChemSec, calling for them to halt the production of persistent “forever chemicals”.

The EU ban on PFAS
The proposed EU ban on PFAS is extensive and the first of its kind worldwide. The idea was initially initiated by Sweden, Denmark, the Netherlands, Germany and Norway, who have spent almost three years mapping the implications of a ban on PFAS chemicals in a dossier that expands over nearly 2000 pages. The proposal shows, among other things, that the emissions of PFAS were 75 000 tonnes in 2020. If this continues, the emissions are expected to sit at 4.4 million tonnes in 30 years. The emissions originate from the production and use of the many products that contain PFAS; furniture, cosmetics, electronics and many more.

Hologenix announces that CELLIANT® with REPREVE®, a performance fiber made from recycled materials and enhanced with IR technology, has been shortlisted for the Drapers Sustainable Fashion 2023 Awards. Introduced with global textile solutions provider UNIFI® makers of REPREVE®, CELLIANT with REPREVE is honored in the Sustainable Textile Innovation Category of the awards.

The Drapers Awards recognize the strides that are being made in reducing the industry’s environmental impact and creating fairer working conditions across the supply chain. According to Drapers the quality and quantity of entries were higher than ever this year. Judging was underpinned by the UN-backed Sustainable Development Goals. Winners will be announced at a ceremony on May 25, 2023 at The Brewery in London.

This recognition is the second award for CELLIANT with REPREVE since its launch in the fall of 2022 – it was previously named a Selection in the Fibers & Insulation Category of ISPO Textrends Fall/Winter 2024/25. This is also the second year in a row that a Hologenix innovation has been shortlisted for the Drapers Sustainable Fashion Awards.

CELLIANT is a natural blend of IR-generating bioceramic minerals, which, when embedded into textiles, allows them to convert body heat into infrared energy, returning it to the body and temporarily increasing local circulation and cellular oxygenation. This aids significantly in muscle recovery, increases endurance and improves overall performance in healthy individuals, among other benefits.

REPREVE recycled performance fiber consists of high-quality fibers made from 100% recycled materials, including post-consumer plastic bottles and pre-consumer waste. It is also certified and traceable with UNIFI’s U TRUST® verification and FiberPrint™ technology, which provide assurance that the product comes from recycled materials. Compared to virgin fiber, REPREVE helps to offset the use of petroleum, conserving water and energy and emitting fewer greenhouse gasses.

• Registered in majority as a class 1 medical device  

CELLIANT -  a performance textile that converts body heat into infrared energy - is designated as a Class 1 Medical Device in Australia, Canada, the EU and European Economic Area (EEA), Japan, New Zealand, the United Arab Emirates, the United Kingdom and the United States. CELLIANT is cleared to market in China, India, Indonesia, Korea, Malaysia, Mexico, Peru, Philippines, Russia, Saudi Arabia, Singapore, South Africa, Taiwan, Thailand and Vietnam, with more countries and regions to follow.

In 2017, the FDA determined that products containing CELLIANT are medical devices as defined in section 201(h) of the Federal Food, Drug and Cosmetic Act and are general wellness products because they are intended to temporarily increase blood flow and local circulation at the site of the application in healthy individuals.
 
At Hologenix®, whose CELLIANT® infrared technology is an ingredient in world-class brands across many categories, science matters. The company has a distinguished Science Advisory Board composed of experts in the fields of photobiology, nanotechnology, sleep medicine, diabetes and wound care. The Science Advisory Board has overseen nine peer-reviewed published studies that collectively demonstrate CELLIANT’s effectiveness and the benefits of infrared energy. This claim set provides the basis for products containing CELLIANT to be designated as a Class 1 Medical Device in 38 countries and cleared to market in 15, with more countries and regions to follow. This elevated status in 53 countries translates to CELLIANT being an ideal partner for global companies who are seeking innovation in textiles to distinguish their products.   

“We have laid the groundwork for our partner brands to capitalize on the benefits of our infrared technology and to enhance their ability to do business,” said Seth Casden, Hologenix co-founder and CEO.  “We firmly believe that regulatory status matters and that is why we have grown the number of countries we have such relationships with by over a third in the last three years. It is definitely a competitive advantage of our company and CELLIANT.”

“Globally, the awareness of the benefits of infrared textiles, which absorb body heat and reflect it back as therapeutic infrared energy, has grown exponentially over the last 10 years,” continued Casden. “And in the United States infrared is gaining a strong foothold.”

Hologenix®, creators of CELLIANT®, is pleased to announce CELLIANT® with REPREVE® – introduced with global textile solutions provider UNIFI®, makers of REPREVE® – has been awarded a Selection in the Fibers & Insulation Category of ISPO Textrends Fall/Winter 2024/25.

Twice a year, ISPO recognizes innovative fibers, fabrics and components that are used to manufacture sports apparel. Both companies are excited that CELLIANT® with REPREVE®, whereby CELLIANT infrared (IR) technology is embedded into REPREVE, a brand of recycled fiber, has achieved the honor. CELLIANT® with REPREVE® is a performance fiber made from recycled materials that have been enhanced with IR technology to provide wellness benefits to the consumer.

CELLIANT is a natural blend of IR-generating bioceramic minerals, which, when embedded into textiles, allows them to convert body heat into infrared energy, returning it to the body and temporarily increasing local circulation and cellular oxygenation. This aids significantly in muscle recovery, increases endurance, and improves overall performance in healthy individuals, among other benefits.

REPREVE recycled performance fiber consists of high-quality fibers made from 100% recycled materials, including post-consumer plastic bottles and pre-consumer waste. It is also certified and traceable with UNIFI’s U TRUST® verification and FiberPrint™ technology, which provide assurance that the product comes from recycled materials. Compared to virgin fiber, REPREVE helps to offset the use of petroleum, conserving water and energy and emitting fewer greenhouse gasses.

This award marks the third year in a row that Hologenix has had its CELLIANT technology recognized in the Fall/Winter Textrends Awards. CELLIANT in pure white was a Top Ten Winner in last year’s awards. The prior year, CELLIANT Viscose was a Selection Winner as well.

HeiQ will present a host of innovative technologies to battle those enemies of sleep represented by heat, odor, and inanimate allergens, thereby addressing one of the most underrated elements that hinder a healthy life: a good night’s sleep.

HeiQ has developed technologies that promote better sleep quality for all:

• HeiQ Cool - one of the first textile technologies to deliver both instant contact cooling and continuous evaporative cooling for optimal well-being during sleep.
• HeiQ Mint - a plant-based deodorizer that controls odor development on textiles, providing fabrics with a long-lasting odor control capability that keeps textiles smelling fresh for longer.
• HeiQ Allergen* Tech - a 100% biobased, proprietary technology that reduces exposure to allergens such as house dust mite matter, and pet allergens with the help of active probiotics. The technology is tested and certified by an accredited lab, BMA Labor in Bochum, Germany, and has been granted the Allergy UK Seal of Approval by The British Allergy Foundation.

These effective ingredients are already being applied to final products by HeiQ’s partners. Among them are Trendsetter/John Lewis pillows, duvets, and mattress protectors (with HeiQ Cool & HeiQ Allergen Tech), Trident Jiva Hypoallergenic bed linen (with HeiQ Allergen Tech), Belfama shower towels (with HeiQ Mint), and Lameirinho bed linen/bed sheets (with HeiQ Allergen Tech).

The above mentioned and HeiQ will showcase their new products at Heimtextil 2023 in Frankfurt, Germany, 10- 13 January 2023.

Hologenix®, creators of CELLIANT®, began 20 years ago with the idea of improving the quality of people's lives and health with an emphasis on non-invasive, natural, holistic healing. Co-founder and CEO Seth Casden became fascinated with the effect infrared has on the body and worked with a dedicated team to develop and market CELLIANT® infrared technology and thus materials science innovator Hologenix came to be.

CELLIANT, a proprietary blend of IR-generating bioceramics that are ethically sourced, is a unique combination of nature and performance. CELLIANT captures and converts body heat into infrared energy for increased local circulation and cellular oxygenation, resulting in stronger performance, faster recovery and better sleep. It is a key ingredient in textiles, spanning both performance and fashion apparel, sleep and lounge wear, bedding, upholstery, uniforms and medical supplies.

The first partnership Hologenix secured was with the Ireland-based fiber company Wellman International Limited, a fully owned subsidiary of Indorama Ventures and a pioneer in recycling technologies. Hologenix still works with them today, a tribute to the company’s ability to form long-term partnerships with like-minded organizations, and their joint project of pure white CELLIANT rPET fiber was shortlisted for a prestigious Drapers Sustainable Fashion Award earlier in the year.

On the brand side, many of the first brands to incorporate CELLIANT were in the sportwear industry, including Adidas, Reebok, Saucony, Eastern Mountain Sports, Sierra Designs sleeping bags and Superfeet insoles.

In 20 years, Hologenix has achieved many scientific milestones, and CELLIANT has been and continues to be rigorously tested by a Science Advisory Board composed of experts in photobiology, nanotechnology, sleep medicine, and diabetes and wound care. The Science Advisory Board has overseen nine peer-reviewed published studies that demonstrate CELLIANT’s effectiveness and the benefits of infrared energy.

Looking ahead, Hologenix is continuing to research applications for CELLIANT in the agriculture industry and wound healing and diabetes. Expansion into the FemTech market with both product applications and scientific research about the benefits of infrared for women’s health issues is also on the horizon.

Medline, a medical product distributor and manufacturer, together with Hologenix® launched a new line of CURAD® Performance Series® orthopedic products powered by CELLIANT® infrared technology.

CELLIANT, the flagship innovation of Hologenix, is a proprietary blend of natural minerals that allows textiles to convert body heat into infrared energy, returning it to the body and temporarily increasing local blood flow and cellular oxygenation. This has been clinically demonstrated to support recovery from physical activity and fatigue, increase endurance and stamina, and boost overall performance in healthy individuals, among other benefits.  

Trusted by athletes, CURAD is the Official Medical Supplier of the IRONMAN® U.S. Series. The new orthopedic products powered by CELLIANT infrared technology are the latest additions to the CURAD Performance Series collection and including different infrared supports designed for the ankle, knee, back, shoulder, as well as multipurpose use.

“This new CURAD Performance Series offering represents a major expansion of CELLIANT infrared (IR) bio-responsive textiles into the sports medicine field,” said Seth Casden, Hologenix Co-Founder and CEO. “We are honored to partner with Medline and look forward to future introductions.”

In addition to the inclusion of CELLIANT infrared technology, Medline has engineered the elastic supports to provide targeted compression for enhanced local circulation that helps reduce swelling, with a contoured fit that won’t slip or shift during normal activities with silicone grips that keep the product in place.

The removable hot/cold therapy supports provide adjustable compression and a gel compress that can be cooled or heated to further reduce swelling and discomfort.

Freudenberg Performance Materials (Freudenberg) has launched an elastic variant of its flexible superabsorbers for modern wound dressings. These superabsorbers increase the comfort level for patients as well as enabling longer wear time, thus reducing the frequency of dressing changes. Freudenberg is debuting the elastic superabsorbers at this year’s Compamed in Düsseldorf, from November 14 – 17, 2022. Further highlights at the trade fair include components for more sustainable wound care, PU foams with directly applied silicone adhesives, and an innovative hydrophilic debridement foam.

Freudenberg uses a new technology to manufacture the elastic superabsorbers. Unlike other methods, this technology does not perforate or slit the material, thus achieving a high degree of consistent elasticity. Furthermore, the technology used by Freudenberg bonds the superabsorbent fibers more uniformly with the material, thus enhancing the integrity of this layer in the wound dressing.

“Our new elastic superabsorbers demonstrate yet again how Freudenberg components help increase comfort for patients, reduce the workload for nursing staff and lower healthcare costs. Our extensive technology platform and our innovative strength are the basis for this,” Dr. Henk Randau, SVP and General Manager Global Division Healthcare at Freudenberg Performance Materials, said.

During an awards ceremony on Monday, October 17, the Society for Human Resource Management (SHRM) Foundation awarded Barry-Wehmiller CEO Bob Chapman its preeminent recognition in people leadership, the Tharseō CEO of the Year Award.

SHRM is the world's largest HR professional society, representing more than 300,000 HR professionals across the globe, impacting 115 million workers and their families. The Tharseō (thar-seh'-ō)—derived from the Greek word for "courageous, confident and bold"—awards are given to those who demonstrate innovative and impactful business practices leading to better workplaces and a better world by serving as visionaries, innovators and change agents.

Chapman has been the CEO of Barry-Wehmiller since 1975. Since then, he has applied a blend of strategy and culture to create a thriving global organization. Chapman’s work is chronicled in his 2015 Wall Street Journal bestseller Everybody Matters: The Extraordinary Power of Caring for Your People Like Family, co-authored by Raj Sisodia, founder of Conscious Capitalism. In 2016, Harvard Business School released a case study about Barry-Wehmiller’s approach to business that is now taught at 80 business schools. A non-profit, Chapman Foundation for Caring Communities, and a leadership consulting firm, Chapman & Co. Leadership Institute, bear Chapman’s name and share some of the foundational learnings that helped transform the culture of once-traditional Barry-Wehmiller into a caring, dignity-honoring, fulfilling place to work.

In recent years, Chapman has focused on creating caring leaders of tomorrow by sponsoring programs in K-12 schools and universities. In 2021, Chapman and his team partnered with Fordham University and other Jesuit business schools to launch the Humanistic Leadership Academy which helps professors and students become more human-centered.

A sought-after global speaker, Chapman recently addressed the United Nations PRME conference on transforming education, the China Organizational Evolution Forum, Brazil’s Virtuous Leadership Conference, Vizient CEO Network, and the Healthcare Burnout Symposium, to name a few.